Loading
Led the Dutch-Danish trial that proved TIL therapy beats ipilimumab in melanoma, the first randomised win for a cell therapy in a solid tumour.
Inge Marie Svane (Herlev, Denmark) co-led with John Haanen the randomised phase 3 trial showing tumour-infiltrating lymphocyte therapy doubles progression-free survival compared with ipilimumab in advanced melanoma, the first randomised evidence for any cell therapy in a solid tumour. She built Denmark's academic TIL manufacturing programme and leads trials of TIL in other cancers and of peptide vaccines targeting IDO and PD-L1.
Shares Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma, Lifileucel, TIL therapy, Ipilimumab.
Shares Lifileucel, TIL therapy, Melanoma.
Shares Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma, Lifileucel, TIL therapy, Ipilimumab.
Shares Lifileucel, TIL therapy, Melanoma.
Shares TIL therapy, Melanoma and the tag cell-therapy.
Shares Lifileucel, TIL therapy, Melanoma.
Shares Ipilimumab, Melanoma and the tag melanoma.
Shares Lifileucel, TIL therapy, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/